Blueprint Medicines Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BLUEPRINT MEDICINES, and what generic alternatives to BLUEPRINT MEDICINES drugs are available?
BLUEPRINT MEDICINES has one approved drug.
There are four US patents protecting BLUEPRINT MEDICINES drugs.
There are forty patent family members on BLUEPRINT MEDICINES drugs in thirty-one countries and sixteen supplementary protection certificates in fourteen countries.
Summary for Blueprint Medicines
International Patents: | 40 |
US Patents: | 4 |
Tradenames: | 1 |
Ingredients: | 1 |
NDAs: | 1 |
Drugs and US Patents for Blueprint Medicines
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-001 | Jan 9, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-001 | Jan 9, 2020 | RX | Yes | No | 9,200,002 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-003 | Jan 9, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-005 | Jun 16, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-003 | Jan 9, 2020 | RX | Yes | Yes | 9,944,651 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-005 | Jun 16, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-002 | Jan 9, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Blueprint Medicines Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
South Korea | 102378689 | ⤷ Try a Trial |
Japan | 2016538257 | ⤷ Try a Trial |
Taiwan | I683814 | ⤷ Try a Trial |
Japan | 6446040 | ⤷ Try a Trial |
Hong Kong | 1221461 | ⤷ Try a Trial |
Hungary | E059041 | ⤷ Try a Trial |
Russian Federation | 2706235 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Blueprint Medicines Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3057969 | 2021C/509 | Belgium | ⤷ Try a Trial | PRODUCT NAME: AVAPRITINIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/20/1473 20200925 |
3057969 | LUC00199 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: AVAPRITINIB ET SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/20/1473 20200925 |
3057969 | PA2021003 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: AVAPRITINIBAS IR JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS; REGISTRATION NO/DATE: EU/1/20/1473 20200924 |
3057969 | CA 2021 00008 | Denmark | ⤷ Try a Trial | PRODUCT NAME: AVAPRITINIB OG FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/20/1473 20200925 |
3057969 | C20210005 00320 | Estonia | ⤷ Try a Trial | PRODUCT NAME: AVAPRITINIIB;REG NO/DATE: EU/1/20/1473 25.09.2020 |
3057969 | 10/2021 | Austria | ⤷ Try a Trial | PRODUCT NAME: AVAPRITINIB UND PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/20/1473 (MITTEILUNG) 20200925 |
3057969 | 122021000014 | Germany | ⤷ Try a Trial | PRODUCT NAME: AVAPRITINIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/20/1473 20200924 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.